AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01149148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INVOS Somanetics Cerebral Oximeter
Description: INVOS Cerebral Oximetry blinded monitoring with no deviation in surgical procedures or standard of care in anesthesia.
Study NCT03855826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifekalant hydrochloride
Description: Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
Study NCT00665457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Study NCT00665457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: needle biopsy
Study NCT03855826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
Study NCT00665457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00665457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiomammography
Study NCT00665457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound imaging
Study NCT05736900 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sampling
Description: One samples of 5 mL blood is taken into a Serum tube for measurement of the RAAS-Biomarkers. After allowing to coagulate between 30 min and 60 min at room temperature, samples are centrifuged at 3000g for 10 min at room temperature.
Study NCT04264481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Ultrasound guided perineural injection of 5cc bupivacaine, 5cc lidocaine and 10 cc Normal saline
Study NCT00513409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: Intramuscular injection, 1 or 2 doses
Study NCT04264481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Articular Steroid and Lignocaine Injection
Description: Intra-articular injection of 40mg triamcinolone and 1-2 cc of lidocaine
Study NCT03202602 — intervention group
Intervention type: OTHER
Intervention: Telemonitoring of CPAP treatment
Description: Telemedicine technology allows for monitoring of CPAP pressure, air leaks, apnea-hypopnea index (AHI) and compliance on a daily basis.
Study NCT03202602 — intervention group
Intervention type: OTHER
Intervention: Standard care
Description: Office visits and monitoring of CPAP treatment at each visit.
Study NCT02431962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Low dose chest CT screening annually x 3
Study NCT04132713 — intervention group
Intervention type: DRUG
Intervention: Capecitabine 150Mg Oral Tablet
Description: Advanced breast cancer patients with first-line medication
Study NCT02431962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active smokers - Smoking cessation arm
Description: Phone based smoking cessation counseling
Study NCT01241929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video decision aid
Description: video of CPR
Study NCT02431962 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active smokers - Control arm
Description: Subjects will be provided with general information on available smoking cessation resources
Study NCT03260751 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zingiber officinale Roscoe extract 200 mg
Description: 2 cap/day, 800 mg/cap for 12 weeks
Study NCT03260751 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks
Study NCT01777113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity aerobic training
Description: The mode of the training will be uphill treadmill walking in 4x4 minute intervals at 85% and 95% of Heart Rate Peak (HRpeak) precede by 10-minute warm-up period on the treadmill at self-selected speed and inclination. Between the 4-minute intervals, 3-minute active breaks walking at approximately 50% of HRpeak will be applied. The training sessions will be terminated by a 3-minute cool-down period at 50% to 70% HRpeak. To compensate for increased VO2peak, the speed and/or inclination will be gradually adjusted during 3-month intervention to make sure that the target HR will be between 85% and 95% of HRpeak during the high-intensity intervals.
Study NCT01777113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Strength Training
Description: Five warm-up repetitions will be completed at approximately 50% of 1 repetition maximum before the main session of four sets of four repetitions unilaterally at 85%Y95% of 1 repetition maximum for both leg press and plantarflexion. When subjects will be able to complete a fifth repetition, the weight will be increased by 1.25 to 2.5 kg, dependent on subjective feelings of capability. They will be encouraged to focus of an explosive concentric movement and a controlled eccentric movement such that the time on each phase will be in the ratio 1:2. The subjects will be regularly reminded to focus on breathing during the contraction, preventing the valsalva maneuver and high rises in blood pressure. The session will finish with a minimum 5-min warm down the treadmill device.
Study NCT01777113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Training
Description: Conventional training consisted of group mobility, balance and stretching exercises. Mobility training included treadmill and cycloergometer training for 10 minutes at self selected speed. Exercises at the parallel bars included weight shift from leg to leg, half-squat, turn in place, leg-trunk flexion, and extension exercises. Finally seated upper- and lower-limb stretching exercises will focus on range of motion, including trunk mobility.
Study NCT03201107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Training based on a basic level Pilates exercise program will be as follows:~A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty.
Study NCT00883727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem cell
Description: IV infusion of stem cells
Study NCT00883727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Plasmalyte A
Description: IV infusion
Study NCT00513409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix Hexa
Description: 1 Intramuscular injection
Study NCT00513409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: 1 Intramuscular injection
Study NCT01107678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Snacks and Organized Physical Activity
Description: Children in the intervention group will receive healthy snacks, smaller portion sizes and participate in organized physical activity on a daily bais
Study NCT04342221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
Study NCT04342221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT03981237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-activated irrigation with a pulsed Er:YAG laser
Description: The root canals and the pulp chamber are filled with NaOCl 3%. Per canal, the laser tip is placed above the root canal entrance and activated (frequency 20 Hz, pulse energy 20 mJ and pulse length 50 μs) for 30s. TThe canal is then rinsed with NaOCl using a 27G needle, followed by a second application of laser, identical to the first.
Study NCT03981237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonically activated irrigation
Description: The root canals and the pulp chamber are filled with NaOCl 3%. An Irrisafe file, driven by an ultrasonic unit according to the manufacturers' instructions, is held at 1-3 mm from WL (precurved if canal is curved) and activated for 30 s. The canal is then rinsed with NaOCl using a 27G needle. This cycle is repeated three times (i.e. 3\*20s).
Study NCT03981237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthograde root canal treatment
Description: After rubber dam isolation and field disinfection, the pulp chamber is accessed. The root canal(s) is/are located and shaped using manual and mechanical NiTi instruments in combination with NaOCl (3%) irrigant. The canals are dried using paper points and obturated with gutta percha and epoxy resin sealer. The tooth is sealed with a temporary or permanent filling.
Study NCT03981237 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthograde root canal treatment
Description: After rubber dam isolation and field disinfection, the pulp chamber is accessed. The root canal(s) is/are located and shaped using manual and mechanical NiTi instruments in combination with NaOCl (3%) irrigant. The canals are dried using paper points and obturated with gutta percha and epoxy resin sealer. The tooth is sealed with a temporary or permanent filling.
Study NCT00439946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil
Description: rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
Study NCT00439946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crono Five ambulatory pump
Description: Used for administration of IV Remodulin (treprostinil)
Study NCT03426085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 6 mg Solution for Injection
Study NCT03426085 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02268721 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tablet computer
Description: Patients receive a tablet computer upon discharge. The tablet can be used for ordering food for delivery three times a week from the hospital kitchen.
Study NCT04363476 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SHRED Osteoarthritis program
Description: Combined exercise and education intervention
Study NCT02279680 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electroencephalography
Study NCT02279680 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological assesments
Study NCT03551444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of DAA-based treatment
Description: * Antiviral therapy and treatment duration (12/24 weeks) will be indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the EASL Recommendations on Treatment of Hepatitis C 2016.~* HCV-RNA quantification will be assessed by real-time PCR, with a limit of detection (LOD) of15 IU/mL.~* During antiviral treatment, follow-up of the Patients will be monthly by clinical and laboratory evaluation.~* Virological response to DAA-based treatment will be assessed by quantitative HCV-RNA at the end of treatment (EOT) and at 4 and 12 weeks after the EOT, to confirm sustained virological response (SVR).~* SVR12 is defined as undetectable HCV-RNA at week 12 after the EOT.~* Virological failures and early discontinuations of therapy due to adverse events will be also registered.
Study NCT03551444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of DAA-based treatment
Description: * Antiviral therapy and treatment duration (12/24 weeks) will be indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the EASL Recommendations on Treatment of Hepatitis C 2016.~* HCV-RNA quantification will be assessed by real-time PCR, with a limit of detection (LOD) of15 IU/mL.~* During antiviral treatment, follow-up of the Patients will be monthly by clinical and laboratory evaluation.~* Virological response to DAA-based treatment will be assessed by quantitative HCV-RNA at the end of treatment (EOT) and at 4 and 12 weeks after the EOT, to confirm sustained virological response (SVR).~* SVR12 is defined as undetectable HCV-RNA at week 12 after the EOT.~* Virological failures and early discontinuations of therapy due to adverse events will be also registered.
Study NCT02516969 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Radiation
Study NCT03544333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: We will assess safety and efficacy of the following protocol: 1Hz of rTMS over the Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al., 1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
Study NCT03544333 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: We will assess safety and efficacy of the following protocol: 1Hz of rTMS over the Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al., 1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
Study NCT03820622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
Description: patients in the study group will be treated by the Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
Study NCT03820622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-Eluting Balloon (Bingo)
Description: patients in the study group will be treated by the Paclitaxel-Eluting Balloon (Bingo)
Study NCT02301416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine/topiramate
Description: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.
Study NCT02301416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low calorie diet
Description: The low-calorie diet will be individually tailored based on initial resting metabolic rate measurement and co-morbid conditions.
Study NCT03062540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
Study NCT03062540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SL Tablet
Description: Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
Study NCT03238859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real cTBS
Description: This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
Study NCT03238859 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cTBS
Description: This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
Study NCT03656679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pectoralis Blockade (PECs)
Description: Ten milliliters of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited between the pectoralis major and minor (PECs I) and 20 cc of 0.25% bupivacaine with 2.5mcg/ml epinephrine deposited between the pectoralis minor and serratus anterior muscle.
Study NCT03656679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Blockade
Description: 10cc of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited at two levels (T3 and T5) per side while in the sitting position.
Study NCT02750540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir enema
Study NCT04363476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHRED Osteoarthritis program
Description: Combined exercise and education intervention
Study NCT03636633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard respiratory physiotherapy
Description: Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques.
Study NCT02750540 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline enema
Study NCT01032304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdosteine
Description: One 300 mg capsule twice a day
Study NCT01032304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule twice a day
Study NCT03636633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard respiratory physiotherapy and inspiratory muscle training
Description: Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques. Addition to that, threshold IMT device will be used for the training. Training intensity will set at 40% of the maximum inspiratory pressure.
Study NCT03208153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invasive
Description: Coronary angiogram and revascularization if anatomically feasible
Study NCT03208153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative
Description: Conservative
Study NCT01295437 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vypro II mesh
Description: partly absorbable mesh
Study NCT01295437 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Premilene LP
Description: lightweight mesh
Study NCT01295437 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Premilene mesh
Description: A conventional polypropylene mesh (82 g/m2)
Study NCT01374503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0651
Description: single or multiple (once daily for maximum 3 consecutive days) i.v. administration, 0.003-12 mg/kg
Study NCT01374503 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single or multiple i.v. administration
Study NCT01293656 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: There is no study intervention. Participants will be treated locally per site standards.
Study NCT03396263 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-personalised advice
Description: Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalised dietary advice for improved food choice based on standard population health guidelines.
Study NCT03396263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online personalised advice
Description: Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
Study NCT03396263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face personalised advice
Description: Provision of face-to-face personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
Study NCT03859583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: 4 tsp of cayenne in a breakfast omelette
Study NCT03859583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: breakfast omelette without cayenne pepper
Study NCT02744404 — intervention group
Intervention type: DEVICE
Intervention: POC EID
Study NCT02955043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral techniques
Description: Improve nighttime sleep: Participants will receive a modified form of cognitive-behavioral therapy for insomnia with a primary focus on stimulus control, a set of techniques to strengthen the association between bed and sleep and weaken its association with stimulating behaviors.~Increase daytime activity: Participants will receive instruction in activity management strategies including prioritizing activities, planning activities during peak energy, activity pacing, and alternating between rest and activity. Participants will be provided with a basic step-count pedometer to enhance ability to self-monitor activity and increase motivation for activity.~The intervention will be adapted to individual needs based on assessments of sleep and activity patterns.